Silence Therapeutics (SLN) EPS (Basic) (2024 - 2026)

Silence Therapeutics has reported EPS (Basic) for 3 years, with the latest figure at -$0.11 in Q1 2026.

• Quarterly EPS (Basic) rose 47.58% year-over-year to -$0.11 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.53 (down 25.96% YoY) and the FY2025 annual result came in at -$0.63, down 189.32% from the prior year.
• EPS (Basic) declined to -$0.11 in Q1 2026 per SLN's latest filing, from -$0.08 in the prior quarter.
• Over five years, EPS (Basic) peaked at $0.17 in Q4 2024 and troughed at -$0.25 in Q3 2024.
• A 3-year average of -$0.11 and a median of -$0.14 in 2024 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2025 and 2026: EPS (Basic) plunged 1048.66% in 2025, then soared 47.58% in 2026.
• Over 3 years, EPS (Basic) stood at $0.17 in 2024, then tumbled by 147.5% to -$0.08 in 2025, then fell by 27.07% to -$0.11 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.11, -$0.08, and -$0.15 for Q1 2026, Q4 2025, and Q3 2025 respectively.